K
Kristine Torres-Lockhart
Researcher at Harvard University
Publications - 7
Citations - 575
Kristine Torres-Lockhart is an academic researcher from Harvard University. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 2, co-authored 3 publications receiving 475 citations.
Papers
More filters
Journal ArticleDOI
PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Yasir H. Ibrahim,Celina Garcia-Garcia,Violeta Serra,Lei He,Kristine Torres-Lockhart,Aleix Prat,Pilar Anton,Patricia Cozar,Marta Guzman,Judit Grueso,Olga Graciela Cantu Rodriguez,Maria Teresa Calvo,Claudia Aura,Orland Diez,Isabel T. Rubio,José Francisco Pérez,Jordi Rodon,Javier Cortes,Leif W. Ellisen,Maurizio Scaltriti,José Baselga +20 more
TL;DR: It is shown thatPI3K blockade results in HR impairment and sensitization to PARP inhibition in TNBCs without BRCA mutations, providing a rationale to combine PI3K and PARP inhibitors in this indication.
Journal ArticleDOI
Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma
Lei He,Kristine Torres-Lockhart,Nicole Forster,Saranya Ramakrishnan,Patricia Greninger,Mathew J. Garnett,Ultan McDermott,Stephen M. Rothenberg,Cyril H. Benes,Leif W. Ellisen +9 more
TL;DR: The discovery of Mcl-1 as a dominant and tissue-specific survival factor in SCC is uncovered, providing a roadmap for a new therapeutic approach and providing a biochemical rationale and predictive markers for the application of this therapeutic combination in S CC.
Journal ArticleDOI
Clinical Management of Opioid Withdrawal.
TL;DR: A narrative review of evidence-based opioid withdrawal management strategies applicable to a variety of treatment settings and geographies is provided, all guided by a patient-centered approach to care.
Journal ArticleDOI
Management of opioid use disorder, opioid withdrawal, and opioid overdose prevention in hospitalized adults: A systematic review of existing guidelines.
Susan L. Calcaterra,Richard Bottner,Marlene Martin,Honora Englander,Zoe M. Weinstein,Melissa Weimer,Eugene Lambert,Matthew V. Ronan,Sergio A Huerta,Tauheed Zaman,M. Ullal,Alyssa F. Peterkin,Kristine Torres-Lockhart,Megan Buresh,Meghan O'Brien,Hannah Snyder,Shoshana J. Herzig +16 more
TL;DR: Future research should systematically study buprenorphine and methadone initiation and titration among people using fentanyl and people with pain, especially during hospitalization.
Proceedings ArticleDOI
Abstract LB-212: Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.
Lei He,Kristine Torres-Lockhart,Nicole Forster,Saranya Ramakrishnan,Patricia Greninger,Mathew J. Garnett,Ultan McDermott,S. Michael Rothenberg,Cyril H. Benes,Leif W. Ellisen +9 more
TL;DR: Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma, providing a biochemical rationale and predictive markers for the application of this therapeutic combination in SCC.